Mainz Biomed N.V. (QUCY)
NASDAQ: QUCY · Real-Time Price · USD
0.4751
+0.0170 (3.71%)
Apr 6, 2026, 4:00 PM EDT - Market closed
Mainz Biomed Revenue
In the year 2025, Mainz Biomed had annual revenue of $537.08K, down -39.92%. Mainz Biomed had revenue of $250.36K in the half year ending December 31, 2025, a decrease of -36.85%.
Revenue (ttm)
$537.08K
Revenue Growth
-39.92%
P/S Ratio
5.55
Revenue / Employee
$41,176
Employees
26
Market Cap
5.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 537.08K | -356.91K | -39.92% |
| Dec 31, 2024 | 893.99K | -1.49K | -0.17% |
| Dec 31, 2023 | 895.48K | 365.60K | 69.00% |
| Dec 31, 2022 | 529.88K | -47.47K | -8.22% |
| Dec 31, 2021 | 577.35K | 83.78K | 16.98% |
| Dec 31, 2020 | 493.57K | 212.17K | 75.40% |
| Dec 31, 2019 | 281.39K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Inotiv | 514.03M |
| MDxHealth | 107.88M |
| Exagen | 66.58M |
| XWELL | 29.21M |
| Precipio | 24.05M |
| bioAffinity Technologies | 6.16M |
| Insight Molecular Diagnostics | 4.06M |
| iSpecimen | 1.93M |
QUCY News
- 24 days ago - Quantum Cyber (f/k/a Mainz Biomed) Announces Stock Ticker Symbol Change to NASDAQ: QUCY - GlobeNewsWire
- 26 days ago - Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors - GlobeNewsWire
- 2 months ago - Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting - GlobeNewsWire
- 4 months ago - Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America - GlobeNewsWire
- 5 months ago - Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025 - GlobeNewsWire
- 5 months ago - Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS) - GlobeNewsWire
- 6 months ago - Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project - GlobeNewsWire
- 7 months ago - Mainz Biomed Announces Registration of ColoAlert in the United Kingdom - GlobeNewsWire